News
StockStory.org on MSN2d
Q1 Earnings Recap: Bristol-Myers Squibb (NYSE:BMY) Tops Branded Pharmaceuticals StocksQuarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same ...
AstraZeneca’s top medical executive Cristian Massacesi will replace Bristol Myers’ current chief medical officer, Samit ...
Bristol-Myers Squibb Co.’s chief medical officer is stepping down from his role after six years at the company, a surprise ...
Bristol Myers Squibb appoints Cristian Massacesi as EVP, Chief Medical Officer, & Head of Development starting Aug 2025.
US pharma major Bristol Myers Squibb revealed it has appointed Dr Cristian Massacesi as executive vice president, chief medical officer and head of development, effective August 1, 2025.
According to Benzinga Pro, Bristol-Myers Squibb's peer group average for short interest as a percentage of float is 3.41%, which means the company has less short interest than most of its peers. Did ...
Bristol Myers Squibb has appointed Cristian Massacesi, M.D., as Executive Vice President, Chief Medical Officer, and Head of Development.
New Jersey-based drugmaker Bristol Myers Squibb this month dedicated its first production facility in Indiana, a former north ...
Bristol Myers Squibb's chief medical officer, Samit Hirawat, is leaving the drugmaker to pursue new professional opportunities.
This was the stock's second consecutive day of losses.
StockStory.org on MSN4d
Bristol-Myers Squibb (BMY): Buy, Sell, or Hold Post Q1 Earnings?Over the past six months, Bristol-Myers Squibb’s shares (currently trading at $46.80) have posted a disappointing 18% loss, ...
Bristol Myers Squibb has raided AstraZeneca to find its next chief medical officer (CMO), persuading Cristian Massacesi, M.D.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results